DNLI Denali Therapeutics Inc.
USHealthcareAs of 2026-07-09 16:00
Why DNLI matters now
Denali Therapeutics Inc. (DNLI) is a US stock in Healthcare. The latest InvestLog snapshot shows $27.21 with +1.95% on the session and $4.32B in market capitalization; recent performance reads 1-month +28.71% and YTD +41.19%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-128.4M, and EPS of $-0.69. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -11.3%.
The latest indexable market news headline is "Denali Therapeutics to Give Opening Plenary Address at Alzheimer's Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $31.00; recent insider activity includes BAKER BROS. ADVISORS LP filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.70
P/S
0.00
EV/EBITDA
-6.79
DCF Value
$0.95
FCF Yield
-11.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-52.2%
ROA
-40.1%
ROIC
-46.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-128.4M | $-0.69 |
| Q4 2025 | $0.00 | $-128.5M | $-0.73 |
| FY 2025 | $0.00 | $-512.5M | $-2.97 |
| Q3 2025 | $0.00 | $-126.9M | $-0.74 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$30.80
Target (Median)
$31.00
Target Range
$23.00 - $40.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.01
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.